Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 17/20 | 0.71 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.71 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.71 |
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.66 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | IKBKB | O14920 | 1/20 | 0.55 |
| ▸ | CHUK | O15111 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MYLK | Q15746 | 1/20 | 0.55 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.55 |
| ▸ | JUN | P05412 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131701 | 0.90 | P2RX1 (0.71) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL127962 | 0.83 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL4928355 | 0.83 | P2RX1 (0.76) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL14514568 | 0.83 | MEN1 (0.64) | TMPRSS4MEN1KMT2A | |
| SCHEMBL3277747 | 0.83 | RUVBL1 (0.56) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL3497353 | 0.80 | P2RX1 (0.72) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL15934966 | 0.80 | P2RX1 (0.80) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL130143 | 0.80 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL3278020 | 0.78 | P2RX1 (0.68) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL11001524 | 0.77 | KDR (0.73) | P2RX1P2RX7P2RX4MEN1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | P2RX1 4560/4885P2RX7 4213/4885P2RX4 4767/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | P2RX1 2484/4885P2RX7 2360/4885P2RX4 3324/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | P2RX1 4850/4885P2RX7 4811/4885P2RX4 4871/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | P2RX1 2927/4885P2RX7 2720/4885P2RX4 3704/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | P2RX1 4680/4885P2RX7 4646/4885P2RX4 4774/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | P2RX1 3156/4885P2RX7 3197/4885P2RX4 4233/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2425/4885P2RX7 2267/4885P2RX4 3298/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2389/4885P2RX7 2289/4885P2RX4 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.